BridgeBio Pharma Inc BBIO

US Biotechnology

$80.09 ▼ -2.50% ($-2.05)

📅 Earnings This Week

Open $82.38

Prev Close $82.14

Day Range $79.46 – $82.40

52W Range $42.09 – $93.42

Market Cap $15.70B

Beta 0.97

EPS (TTM) $-3.75

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-06-27
Shares Out.	195,860,000
Website	bridgebio.com/ ↗
Phone	13026587581
Employees	839
Revenue	$194.5M
Gross Profit	$184.6M
Net Income	-$166.6M
Free Cash Flow	-$445.1M
Total Assets	$1.37B
Total Liabilities	$3.64B
Equity	-$2.27B

About BridgeBio Pharma Inc

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Inc is a publicly traded company under the ticker symbol BBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.